Disease-free survival at 5 years 5 year from date of complete remission [clinicaltrials_resource:0cf5e76dc05a3ead22970916f8d7945b]
Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Disease-free survival at 5 years 5 year from date of complete remission [clinicaltrials_resource:0cf5e76dc05a3ead22970916f8d7945b]
Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
Bio2RDF identifier
0cf5e76dc05a3ead22970916f8d7945b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0cf5e76dc05a3ead22970916f8d7945b
measure [clinicaltrials_vocabulary:measure]
Disease-free survival at 5 years
time frame [clinicaltrials_vocabulary:time-frame]
5 year from date of complete remission
description
Application of combination che ...... ible donor for allogeneic SCT)
identifier
clinicaltrials_resource:0cf5e76dc05a3ead22970916f8d7945b
title
Disease-free survival at 5 years 5 year from date of complete remission
@en
type
label
Disease-free survival at 5 yea ...... 5e76dc05a3ead22970916f8d7945b]
@en